Biographies

Michael Ero

Mr. Ero is the president and CEO of Machaon Diagnostics, a company he founded in 2003. He brings an entrepreneurial approach to laboratory medicine, designing new and innovative laboratory services to meet unmet needs in the healthcare and bioscience industries. With over 20 years of experience in medical laboratory diagnostics, Mr. Ero and his team of scientists have pioneered multiple disruptive laboratory techniques and processes that have revolutionized how life-threatening diseases can be managed and characterized. He has been primary investigator on over 130 clinical trials and studies with physical, molecular, immunologic, platelet and special coagulation endpoints.

Prior to founding Machaon Diagnostics, Mr. Ero was vice president of the Coagulation Center, Inc. of Oakland, California prior to its acquisition by Quest Diagnostics (NYSE:DGX). He has held past clinical and research roles with The Scripps Research Institute, Loyola University Medical Center and the University of Illinois, Chicago. Mr. Ero is the founder and board chairman of Labs4Free, a charitable organization (501c3) that provides laboratory services to underserved populations.

He holds an MBA from Babson College and a BS in medical technology from Michigan State University. He is California-licensed clinical laboratory science and a board-certified medical technologist.

He loves spending time with his wife and son.  Mike is an avid golfer, biker, swimmer, runner and amateur triathlete.

Mike can be reached at mike.ero@machaondiagnostics.com

Brad Lewis, MD

Dr. Lewis is the Medical Director of Machaon Diagnostics. Dr. Lewis is an expert in benign hematology with a focus on thrombosis and hemostasis. He regularly lectures around the US and internationally on the clinical and laboratory approaches to diagnosing atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH). He is a practicing hematologist and directs the hematology department at San Francisco General, a UCSF medical center affiliate. Dr. Lewis has provided clinical consultation on the majority of the greater than 300 suspected cases of aHUS sent to Machaon Diagnostics for complement and coagulation gene sequencing. He has built a unique-to-Machaon, expertise in the use of genetic sequencing data in the acute clinical setting when diagnosis has yet to be established. See our aHUS Genetic Panel (48-hour STAT) for more information.

Dr. Lewis holds a BS in History from MIT, an MA from Brandeis University and an MD from the UCLA School of Medicine.

Brad can be reached at brad.lewis@machaondiagnostics.com

Gloria Coker, MD

Dr. Coker is the Medical Director of Louisiana Coagulation, a division of Machaon Diagnostics. Dr. Coker took on this role in 2016 after having founded and lead Louisiana Coagulation since its founding in 1991. Dr. Coker is internationally recognized for her expertise in thrombosis and hemostasis. Dr. Coker is a pathologist and also a Clinical Assistant Professor of Medicine in Hematology/Medical Oncology at Tulane University Health Sciences Center. Dr. Coker holds a medical license from the Louisiana State Board of Medical Examiners and certifications from the American Board of Clinical & Anatomical Pathology and The International Board of Clinical & Applied Thrombosis Hemostasis and Vascular Medicine.

Dr. Coker received her medical degree from Tulane Medical School and completed her internship and residency in Pathology at Ochsner Foundation Hospital in New Orleans.

Jamey Kain, PhD

Dr. Jamey Kain is Director of Genetic Innovation at Machaon Diagnostics. He leads the effort to clinically validate various rapid genetic sequencing services associated with thrombotic disorders. Dr. Kain’s publications include articles in Nature, PNAS and several other scientific journals.

Dr. Kain comes from a diverse academic background. He completed a postdoctoral fellowship where he used machine vision, machine learning and automation to study the roles of nature, nurture and noise in behavior at Harvard University. Dr. Kain holds a PhD in Biochemistry and a MA in Biology from Harvard where he studied the role of proteolysis during bacterial development. As an undergraduate (BA in Molecular and Cellular Biology from the University of California, Berkeley), he had the good fortune to study aging and DNA damage under Prof. Bruce Ames, the inventor of the famous Ames test.

 

Yamini Bynagari, PhD

Dr. Yamini Bynagari is Director of Clinical Research at Machaon Diagnostics. Dr. Bynagari is a internationally recognized expert in the field of thrombosis and hemostasis. She manages the contract research organization (CRO) assay development experimental design effort at Machaon Diagnostics. Her expertise includes thrombin generation, platelet activation signal transduction and coagulation protein biochemistry. Dr. Bynagari was a joint postdoctoral scholar at Pfizer Center for Therapeutic Innovation and UCSF where she worked with Dr. Shaun Coughlin in the Cardiovascular Research Institute. Dr. Bynagari has published her research in Blood, the Journal of Biological Chemistry and the Journal for Thrombosis and Haemostasis in addition to other high-impact scientific journals. She is a peer-reviewer of Thrombosis Research, Journal of Receptors and Signal Transduction.

Dr. Bynagari holds a PhD in Molecular and Cellular Physiology from Temple University and a BS in Industrial Biotechnology from Anna University in Chennai, India.

Alexander Joyner, PhD

Dr. Alexander Joyner is a Senior Clinical Bioinformatics Scientist at Machaon Diagnostics.  He joined Machaon after three years working in research and development for a leading biotechnology corporation.  He brings specific expertise in the analysis of next-generation sequencing data and variant interpretation.  Dr. Joyner holds a PhD in Biomedical Sciences, with a focus in Bioinformatics, from the University of California, San Diego, an MS in Bioengineering (also from UCSD), and a BA in Biology and Computer Science from the College of William and Mary in Williamsburg, VA.

Tamara Mihailovski, MSCLS

Ms. Mihailovski is the quality manager and technical supervisor at Machaon Diagnostics. She is a founding scientist of the laboratory.  Ms. Mihailovski has been trained in Good Clinical Laboratory Practices (GCLP) such as GLP, GCP, GDocP and other regulatory requirements for clinical trial operations and data management. Ms. Mihailovski has been involved in clinical hematology and oncology for the last 20 years and oversees the SNP, chemiluminescence, cellular and ELISA-based assays.  She manages quality control, management and improvement activities in all sections of the laboratory at Machaon Diagnostics.

She holds a BA from the University of California, Berkeley and a masters in clinical laboratory science from the University of California, San Francisco. Ms. Mihailovski is a California-licensed and NCA-certified clinical laboratory scientist.

Jooeun Lim Choi, PhD

Dr. Jooeun Lim Choi is Senior Clinical Research Scientist at Machaon Diagnostics. Dr. Choi is deeply involved with our Next Generation Sequencing work, running both clinical and research samples. Dr. Choi’s has been published in the Journal of Biological Chemistry and Molecular Microbiology. Prior to pursuing her PhD, Dr. Choi worked at the Paul Prince Laboratory at the University of California, San Diego.

Dr. Choi hold a PhD in Biochemistry from Harvard University an MA in Biology from Harvard University and a BA in Biochemistry and Cell Biology from the University of California, San Diego.

Connie Ng, CLS

Connie Ng is a clinical laboratory scientist (CLS) at Machaon Diagnostics. She is a specialist in special coagulation and next generation sequencing.  She has been trained in Good Clinical Laboratory Practices (GCLP) such as GLP, GCP, GDocP and other regulatory requirements for clinical trial operations and data management.

Ms. Ng holds a BS in Molecular and Cell Biology from the University of California, Berkeley and is a California-licensed clinical laboratory scientist.  She is enrolled in the MPH program at University of California, Berkeley.

Walter Jeske, PhD

Dr. Jeske assists Machaon Diagnostics with the planning and execution of clinical trials and contract research studies. He is an associate professor in the Department of Thoracic and Cardiovascular Surgery and Pathology at Loyola University Medical Center. He has been principal or co-investigator on over 40 clinical trials and studies. Dr. Jeske has authored or co-authored over 400 articles, book chapters and abstracts in the fields of thrombosis, hemostasis and platelet pathophysiology.

Dr. Jeske holds a PhD in Pharmacology from Loyola University, Chicago and a BS in Biochemistry from Illinois Benedictine College.

Bjorn Stromsness

Bjorn Stromsness is the Director of Client Services at Machaon Diagnostics. In this capacity he is responsible for contracting, client services and corporate relationship management. He is also responsible for identifying new service opportunities and communicating how rapid turnaround times can lead to better patient outcomes and new found efficiencies for healthcare providers of all shapes and sizes.

Mr. Stromsness received a BA in History and International Studies from Sonoma State University. Before joining Machaon Diagnostics, Mr. Stromsness was the Director of Business Development at a Silicon Valley enterprise software startup. He also has extensive nonprofit experience, having worked in development and program capacities for Friends of the River, Community Foundation Silicon Valley and the Shasta Regional Community Foundation.

Mr. Stromsness enjoys fly fishing, writing and cooking.

Bjorn can be reached at bjorn@machaondiagnostics.com

Timothy Shurtleff, MPA

Timothy Shurtleff is Machaon Diagnostics’ Health Policy & Government Affairs Analyst and our Laboratory Administrator.

Mr. Shurtleff holds BAs in Psychology and Business Economics from University of California, Santa Barbara and a Masters in Public Administration from California State University, East Bay. His previous employment includes the City of Livermore Housing and Human Services Division and the Oakland-based nonprofit First Place for Youth. Mr. Shurtleff is a founding member of Labs4Free, a charitable organization that provides laboratory services to underserved populations.

His duties include healthcare policy research & advocacy, billing and customer service.

Mr. Shurtleff enjoys the great outdoors, traveling, and sports.

Sheila Flaherty, CLS

Ms. Flaherty brings 38 years of esoteric clinical coagulation testing experience to Machaon Diagnostics. She is the former laboratory manager of the Coagulation Center, Inc. of Oakland, California where she worked in coagulation and platelet diagnostics laboratory testing from 1974 to 2003. Prior to that, Ms. Flaherty held thrombosis-related research positions with San Francisco General Hospital and UCSF Medical Center from 1965 to 1974.

Ms. Flaherty holds a BS in Biology from the University of Michigan and received her laboratory medicine training from Hahneman Hospital in San Francisco, California.

Panels
Tests
Order Forms
Collection Guide
Education and Publications
Clinical Trial Services
Patients

Panels

Panel Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
PlateletGenex Functional Defect Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
aHUS Genetic Panel 48 hours (M-F, two consecutive business days required) Yes EDTA whole blood
Alport Syndrome Genetic Panel 2 business days Yes EDTA whole blood
Heparin Antibody Confirmation Panel < 24 hours (M-F) Yes serum
Hypercoagulability Panel < 24 hours No citrated plasma
von Willebrand Factor Profile with Multimer < 5 days No citrated plasma
Lupus Anticoagulant Screen < 24 hours No citrated plasma
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Prolonged aPTT Evaluation Panel < 24 hours No citrated plasma
Prolonged PT Evaluation Panel < 24 hours No citrated plasma
Plavix Sensitivity Panel < 24 hours Yes citrated whole blood
Mild Bleeding Disorder Panel < 24 hours No citrated whole blood
Dysfibrinogenemia Panel < 24 hours No citrated plasma
Antiphospholipid Antibody Panel < 1 week Yes serum

Tests

Test Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
CFH Autoantibody 48 hours Yes plasma
PFA – Screen (Platelet Function Assessment) < 24 hours No citrated whole blood
ADAMTS-13 Activity < 24 hours (7 days a week) Yes citrated plasma
ADAMTS-13 Inhibitor < 24 hours (7 days a week) Yes citrated plasma
Heparin Antibody Confirmation < 24 hours (M-F) Yes serum
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Activated Protein C – Resistance < 1 week No citrated plasma
ADAMTS-13 Antibody < 3 days Yes citrated plasma
Alpha-2 Antiplasmin Activity < 1 week No citrated plasma
Anticardiolipin Antibody (IgG, IgM, IgA) < 24 hours No serum
Antithrombin III Activity < 24 hours No citrated plasma
Antithrombin III Antigen < 1 week No citrated plasma
aPTT < 24 hours No citrated plasma
aPTT Mixing Study < 24 hours No citrated plasma
aPTT-FS (Factor Sensitive Reagent) < 24 hours No citrated plasma
aPTT-LA (Lupus Sensitive Reagent) < 24 hours No citrated plasma
aPTT-LA Mixing Study < 24 hours No citrated plasma
aPTT-FS Mixing Study < 24 hours No citrated plasma
Beta-2 Glycoprotein I Antibody (IgG, IgM, IgA) < 1 week No serum
Dabigatran (Pradaxa) Level < 24 hours No citrated plasma
Euglobulin Clot Lysis Time < 1 week No citrated plasma
Factor II (2) Activity < 24 hours No citrated plasma
Factor V (5) Activity < 24 hours No citrated plasma
Factor V (5) Leiden Gene Mutation < 24 hours No EDTA whole blood
Factor VII (7) Activity < 24 hours No citrated plasma
Factor VIII (8) Activity < 24 hours No citrated plasma
Factor IX (9) Activity < 24 hours No citrated plasma
Factor X (10) Activity < 24 hours No citrated plasma
Factor X (10) Activity – Chromogenic < 1 week No citrated plasma
Factor X (10) Antigen < 1 week No citrated plasma
Factor XI (11) Activity < 24 hours No citrated plasma
Factor XII (12) Activity < 24 hours No citrated plasma
Factor XIII (13) Activity – Quantitative < 1 week No citrated plasma
Fibrinogen Activity < 24 hours No citrated plasma
Fibrinogen Antigen < 1 week No citrated plasma
Fondaparinux (Arixtra) Level < 24 hours No citrated plasma
Heparin Antibody ELISA (reflex) < 24 hours (7 days a week) Yes serum
Heparin (LMWH) Level < 24 hours No citrated plasma
Heparin (UFH) Level < 24 hours No citrated plasma
Hexagonal Phospholipid aPTT < 1 week No citrated plasma
Homocysteine < 5 days No serum
Inhibitor Screen (aPTT Factors) < 24 hours No citrated plasma
Inhibitor Screen (PT Factors) < 24 hours No citrated plasma
Inhibitor Titer (aPTT Factors) < 24 hours No citrated plasma
Inhibitor Titer (PT Factors) < 24 hours No citrated plasma
Lupus Anticoagulant Index < 24 hours No citrated plasma
MTHFR (A1298C) Gene Mutation < 1 week No EDTA whole blood
MTHFR (C677T) Gene Mutation < 24 hours No EDTA whole blood
Plasminogen Activator Inhibitor Activity < 10 days No citrated plasma
Plasminogen Activity < 5 days No citrated plasma
Plasminogen Antigen < 5 days No citrated plasma
Platelet Electron Microscopy Study < 5 days No ACD whole blood
Platelet Antibody ID – Direct (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No EDTA whole blood
Platelet Antibody ID – Indirect (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No serum
Plavix Sensitivity – Genotype (CYP2C19 Genotyping) < 24 hours No EDTA whole blood
Aspirin Sensitivity – LTA (AA-induced Platelet Inhibition) < 24 hours No citrated whole blood
Ticagrelor Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours citrated whole blood
Brilinta Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Plavix Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Protein C Activity < 24 hours No citrated plasma
Protein C Antigen < 1 week No citrated plasma
Protein S Activity < 24 hours No citrated plasma
Protein S Antigen (Free) < 1 week No citrated plasma
Protein S Antigen (Total) < 1 week No citrated plasma
Prothrombin Fragment 1.2 (F1.2) < 1 week No citrated plasma
Prothrombin Gene Mutation < 24 hours No EDTA whole blood
Prothrombin Time < 24 hours No citrated plasma
PT Mixing Study < 24 hours No citrated plasma
Reptilase Clotting Time < 1 week No citrated plasma
Ristocetin Cofactor Activity < 24 hours No citrated plasma
Ristocetin-induced Platelet Aggregation < 24 hours No citrated whole blood
Rivaroxaban (Xeralto) Level < 24 hours No citrated plasma
Russell Viper Venom Time (dilute) < 24 hours No citrated plasma
Thrombin Generation (normalized-ETP) < 24 hours No citrated plasma
Thrombin Time < 24 hours No citrated plasma
Thrombin/Antithrombin Complex < 1 week No citrated plasma
Von Willebrand Factor Antigen < 24 hours No citrated plasma
Von Willebrand Factor Multimer < 5 days No citrated plasma
Warfarin Sensitivity Genotype (CYP2C9 and VKORC1) < 1 week No EDTA whole blood

Order Forms

Machaon Diagnostics has provided several downloadable documents to assist in ordering, processing and billing. Below please find links to our most frequently requested documents.

Collection Guide

Specimen processing is one of the most important aspects in the generation of accurate and reliable lab results. Many variables, such as, anticoagulant ratio, storage time and temperature, and surface of containers and drawing components can affect test results.

Machaon Diagnostics follows and recommends the use of the third edition of the National Committee for Clinical Laboratory Standards (NCCLS) guideline H21-A3: Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays.

Please contact the lab with any shipping questions

Specimen Collection

Frozen Citrated Plasma
Frozen citrated plasma is the specimen of choice for clotting assays and some ELISA testing. The anticoagulant used for these assays is 105 – 109 mmol/L, 3.13% – 3.2% of the dihydrate form of trisodium citrate (Na3C6H5O7 2H2O), buffered or nonbuffered.

Patients with hematocrit values above 55% should have their final citrate concentration corrected using the following equation:

X = (100 – PCV) / (595 – PCV) WB Volume

Where X is citrate volume required to prepare a whole blood volume (WB Volume) from a patient with a certain percent packed cell volume (PCV).

Please follow the listed suggestions for collection of citrated plasma samples.

  • A 1:9 ratio of anticoagulant to whole blood is imperative
  • Blood should be drawn directly into anticoagulant if possible
  • Syringe draws should be added to anticoagulant within 1 minute
  • Syringe draws should use no more that a 20mL volume syringe
  • A two-syringe technique is preferred for syringe draws
  • Coagulation draws should be the 2nd or 3rd tube drawn
  • Catheter draws should be avoided or under the advice of the attending physician
  • All tubes should be inverted at least 4 times to ensure adequate mixing
  • Suitable needle gauges range from 19 – 22 for coagulation and platelet testing
  • Cell-free plasma must contain less than 10,000 platelets/µL
  • Centrifugation should be performed at 1,500 × g for 15 or more minutes
  • Aliquots are frozen (<= -20ºC) promptly to minimize factor degradation
  • Specimens are shipped frozen on dry ice (-78.5ºC)

Frozen Serum
Frozen serum is the specimen of choice for most immunoglobulin detecting assays and many ELISA based tests. Whole blood is drawn into a glass or plastic tube possibly containing an activator. Please follow the tube manufacturer’s guidelines for tube handling and processing.

Please follow the listed suggestions for collection of serum samples.

  • Plastic tubes containing an activator should be inverted at least 4 times
  • Glass tubes without activator should be clotted for 2 hours at room temperature
  • Suitable needle gauges range from 19 – 22 for the serum based tests
  • Centrifugation should be performed at 1,500 × g for 15 or more minutes
  • Aliquots are frozen (<= -20ºC) before shipping and shipped on dry ice (-78.5ºC

EDTA Whole Blood
EDTA anticoagulated whole blood is the specimen of choice for molecular genetic tests.

Please follow the listed suggestions for collection of genetic samples.

  • Blood should be drawn directly into anticoagulant if possible
  • This must be a closed system draw to prevent contamination
  • All tubes should be inverted at least 4 times to ensure adequate mixing
  • Suitable needle gauges range from 19 – 22 to prevent cell lysis
  • A minimum of 2mL of whole blood is needed for genetic assays
  • No processing is required for this sample type
  • Ship this type of specimen at room temperature

Aliquoting Specimens
Submitting multiple aliquots (plasma or serum) for testing is an important aspect of clot, chromogenic and ELISA based tests. Aliquots of 1mL are requested for most of our assays. These should be frozen prior to shipment in a <= -20 C freezer or colder. Tubes should be placed into a rack to ensure the samples are frozen properly in the base of the tube. Freezing should occur within 1 hour of the time of draw. Please refer to the preferred number of aliquots when submitting samples.

Shipping

Shipment is a crucial aspect of clinical testing. Please follow the below instructions for easy shipments to the lab.

Local Shippers
Machaon Diagnostics contracts with Medical Couriers, Inc. (MCI). who service the entire San Francisco Bay Area and surrounding areas. MCI has a fleet of specially trained drivers that will visit your lab, clinic or office during specified times. Couriers carry dry ice, cold packs and room temperature containers for receipt of all specimen types.

Medical Couriers, Inc. can be phoned for individual pickup requests at the below number.

Medical Couriers, Inc.
(800)-652-1147

Place prepared samples and order forms in a shipping bag with Machaon and specimen type written in a clear and visible location.

Out-of-area Shippers
Please collect the following items:

  • Test Order Form
  • Packing material or newspaper
  • Styrofoam container, possibly with outer cardboard box
  • Packaging tape
  • Airbill for overnight shipments
  • ORM-A label for dry ice shipments (UN1845)
  • Dry ice (-78.5ºC) sufficient for transit time (5lb. per day)
  • Specimens in biohazard specimen transport bag

Packaging
Place the biohazard bag containing samples and the test order form into a Styrofoam container followed by dry ice. Fill remaining container space with packaging material and seal with packaging tape. Adhere a completed airbill and dry ice labels to the exterior of container in a visible location. Telephone your preferred overnight courier to request a pickup or place container in designated pickup area.

Please contact the lab with any shipping questions

Education and Publications

Education

Platelet Functional Defects, from the clinic to genetics (a webinar given by Dr. Brad Lewis, Feb. 24, 2017)

Diagnosing Thrombotic Microangiopathies: TTP and atypical HUS: (A Grand Rounds presentation at Mattel Children’s Hospital, UCLA, to Pediatric Nephrology with Dr. Brad Lewis.)

A guide to the video content:

00:24 – Introduction (Why we should care about diagnosis of aHUS and TTP)
1:00 – What is microangiopathic hemolytic anemia (MAHA)?
1:16 – Blood smear with schistocytes
1:40 – Von Willebrand’s protein synthesis
02:09 – ADAMTS-13 and TTP pathophysiology
02:43 – How to interpret ADAMTS-13 activity testing and advantage of doing ADAMTS-13 activity testing with Machaon Dx
03:48 – Use of ADAMTS-13 testing to diagnose “Occult” TTP
04:40 – Ruling in or out aHUS with ADAMTS-13 activity testing
05:20 – Plasma exchange for aHUS patients
05:57 – The complement cascade and aHUS pathophysiology
08:04 –aHUS patients respond to eculizumab therapy
08:45 – Unlike TTP, aHUS has triggers in 70% of cases
09:26 – aHUS is a multisystem microvascular disease (aHUS-induced organs damage)
10:09 – aHUS presentation
11:41 – Can we differentiate TTP and aHUS clinically?
12:15 – 5 reasons why you should care about aHUS patients genotyping
14:17 – Advantage of doing aHUS genetic testing with Machaon Dx
14:52 – The punchline: aHUS and TTP diagnosis algorithm

Publications

Stromsness B. et al. Perceived clinical utility of ADAMTS-13 testing decreases quickly when turnaround time extends beyond two days. Int J Lab Hematol. 2015; (abstract).

Ero M. et al. Novel variant detection is essential when attempting to genetically confirm the clinical diagnosis of complement-mediated thrombotic microangiopathies (TMA). J Clin Apheresis. 2015; (abstract O-09).

Harbert J. et al. Inhibitory effects of fish oil on platelet-associated thrombin generation as measured by the calibrated automated thrombogram: an in vitro study. Int Soc Thromb Hemost 2014; (abstract 604).

Ero M. et al. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2013;38(2):235-240.

Beattie DT. Et al. An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, Velusetrag and TD-8954. J Thromb Thrombolysis. Vascular Pharmacology. 2013;58:150–156.

Ero M. et al. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single oral daily dose. Alternative Therapies. 2013;19(3): 18-21.

Higgins D. et al. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. Archives of Pharmacology. 2012;385(1):103-9.

Ng C. et al. Oral bioavailability of nattokinase (NSK-SD). Am J Clin Pathol. 2010;134(suppl):11.

Lakshmi P. et al. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Ther. 2010;27(7):1-12.

Jeske WP. et al. Isolation and characterization of heparin from tuna skins. Clin Appl Thromb Hemost. 2007 Apr;12(2):137-45.

Fareed D. et al. Nitric oxide levels are upregulated in patients with malignancy-associated hypercoagulable state. Int J Lab Hematol. 2005; (abstract).

Jeske WP. et al. A survey of venous thrombosis models. Methods Mol Med. 2004;93:221-37.

Sahud et al. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002; 116(4):909-911.

Fenton JW. et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry. 2002;67(1):85-91.

Ero M. et al. Comparative effects of a novel sulfated pentamannan oligosaccaride mixture (PI-88), heparin and related agents on the tissue factor-induced platelet activation and aggregation profile in whole blood. Thromb Haemost. 2001; (abstract 6260).

Ero M. et al. An antiplatelet drug, ticlopidine, inhibits heparin-induced thrombocytopenia responses as measured by platelet aggregometry and 14C serotonin release. Thromb Haemostasis. 1997; (abstract).

Clinical Trial Services

Machaon Diagnostics provides a rapid and complete solution for companies in need of clinical trial services, contract research and independent marketing claim validation. Our team of scientists has over 100 years of clinical study expertise. Machaon Diagnostics has been performing studies on pharmaceuticals, dietary supplements, functional foods and other agents since 2003. Design, subject recruitment, sample collection/storage, testing, statistical analysis, study reporting and manuscript preparation are all included in our comprehensive service. We have an extensive database of well-characterized study volunteers, allowing us to provide some IRB-approved clinical trials in as little as 1 month. Our subject database includes normal adult, elevated risk of cardiovascular disease, high blood pressure, metabolic syndrome and other populations.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Research & Development

Machaon Diagnostics is California’s only independent specialized coagulation lab. We are a privately owned company, staffed by CA-licensed clinical laboratory scientists under the direction of a hematologist medical director.

As a clinical lab, we provide a unique testing environment for evaluating thrombotic, fibrinolytic potential. Pharmaceutical, device and biotech compounds and materials can be studied within established, validated and controlled clinical assays with verified reference ranges. Our clinical tests are further controlled within our quality assurance and proficiency testing policies and procedures. All tests can be modified or re-designed for best-fit analysis.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

The Machaon Diagnostics laboratory facility is located on a medical center campus in Oakland, California and is staffed with over 100 years of in-house esoteric coagulation and platelet testing experience. All lab scientists are published in and passionate about the field thrombosis and hemostasis. Please contact us if we may help with your next study.

Please contact the laboratory to inquire about this service.

Assay Development

Medical procedures, devices, novel agents and methodologies must be evaluated for their impact on coagulation and platelet systems if there is suspected bleeding or clotting potential.

Our staff has had extensive experience designing unique testing systems or applying the proper testing system to answer the client’s questions quickly and accurately.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Please contact the laboratory to inquire about this service.

Patients

What you need to know

If you are reading this page, it likely means your doctor has ordered a bleeding or clotting test for you and would like you to get this test run at Machaon Diagnostics. Machaon Diagnostics is a clinical reference lab specializing in bleeding and clotting testing, one of the few independent coagulation labs in the country. We run very specific, unique blood tests which are often critical in helping doctors determine the correct course of treatment.

Machaon Diagnostics provides specialized lab testing to hospitals and doctors all over the country and is recognized for the speed and quality of our testing.

It is important to know that your insurance may or may not cover your testing. We have a long track record of working with patients to ensure they get the testing they need and we will work with you to help find a solution should your insurance not cover the testing we would provide.

If you are coming in to Machaon for a test, here are some things you will need to have with you:

  • Your doctors lab order
  • Your insurance information
  • Your identification
  • A list of your current medications
  • If you are coming in for a Platelet Aggregation, please remember you must fast before this test.

Machaon Diagnostics was founded in 2003 and is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Please contact the laboratory if you have questions.